- Home
- Supplements
- L-Carnitine
- Increased Energy Production
L-Carnitine for Increased Energy Production
Carnitine reduces fatigue in elderly, dialysis and deficiency populations, with little effect in healthy adults.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 2 g/day L-carnitine or acetyl-L-carnitine with meals; benefit is largely restricted to people who are carnitine deficient
- Expected timeframe
- 4-12 weeks
Protocol
- form
- L-carnitine L-tartrate or acetyl-L-carnitine, the latter crossing the blood-brain barrier and used in fatigue and cognitive trials. Avoid D-carnitine and DL-carnitine
- duration
- 8-12 weeks
- co factor
- Take with meals, ideally containing carbohydrate, since muscle uptake is insulin-dependent. Evidence is mixed and separates by population. Carnitine is essential for transporting long-chain fatty acids into mitochondria for ATP production, so the mechanism is sound, and in genuine deficiency - primary carnitine deficiency, dialysis, valproate therapy, some inborn errors - supplementation clearly restores energy metabolism. Trials in specific fatigued populations, including older adults, dialysis patients, and people with cancer-related or hepatic-encephalopathy-related fatigue, report reductions in fatigue with 2 g/day. In healthy, well-nourished people, muscle carnitine is near saturation and oral supplementation does not raise it without a large insulin stimulus, so an energy benefit is not expected and trials do not find one.
- titration
- Up to 3 g/day in divided doses; do not exceed 4 g/day
- starting dose
- 1 g twice daily with meals
Evidence
What the studies say
No studies are yet linked to both L-Carnitine and Increased Energy Production.
Safety
Caveats
Persistent fatigue deserves investigation before supplementation - anaemia, iron deficiency, thyroid disease, diabetes, sleep apnoea, depression, coeliac disease and malignancy all present this way, and are all treatable. Safety ceiling: doses above 3 g/day commonly cause nausea, vomiting, abdominal cramps, diarrhoea and a fishy body odour; keep below 4 g/day. The TMAO question applies to long-term use: gut bacteria convert carnitine to trimethylamine and then TMAO, a metabolite observationally associated with cardiovascular risk, and supplementation raises it - significance unresolved but a reason for caution with prolonged high-dose use, particularly with existing cardiovascular disease. Carnitine may potentiate warfarin - monitor INR. Avoid in seizure disorders, where increased seizure frequency has been reported, and in hypothyroidism, where carnitine may interfere with thyroid hormone action. Use cautiously in kidney disease, where it accumulates. Insufficient safety data in pregnancy and breastfeeding - avoid in both.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.